FRANKFURT (Reuters) -Switzerland’s Novartis projected currency-adjusted sales growth of 5% to 6% until 2030, underpinned by higher peak revenue expectations for its cancer drugs Kisqali and Scemblix.
The drugmaker lifted the peak sales forecast for Kisqali, used to treat a common type of breast cancer, to at least $10 billion from a previous estimate of $8 billion.
For leukaemia drug Scemblix, Novartis now expects peak sales of at least $4 billion, up from at least $3 billion.
The company said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion.
Last month, it moved to acquire Avidity Biosciences in a $12 billion deal to add muscle-disorder treatment candidates, part of a broader push to offset declining sales of established products, including its heart-failure drug Entresto.
The company has said the planned acquisition would lift its projected annual sales growth for 2024–2029 to 6%, up from the previously expected 5%.
(Reporting by Ludwig Burger; Editing by Christian Schmollinger and Sherry Jacob-Phillips)
